Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $50,648,622.57. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Helen Torley also recently made the following trade(s):

• On Wednesday, October 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $74.44, for a total value of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $68.98 on Friday. The stock has a market cap of $8.07 billion, a PE ratio of 15.78, a P/E/G ratio of 0.38 and a beta of 1.16. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $79.50. The stock has a fifty day simple moving average of $70.45 and a 200-day simple moving average of $61.95.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analysts’ expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company’s revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HALO shares. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Benchmark raised their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Morgan Stanley raised their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Monday, August 18th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $70.44.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HALO. Wealth Preservation Advisors LLC purchased a new position in Halozyme Therapeutics during the 1st quarter worth approximately $32,000. Newbridge Financial Services Group Inc. purchased a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $32,000. SVB Wealth LLC purchased a new position in Halozyme Therapeutics during the 1st quarter worth approximately $33,000. Bessemer Group Inc. grew its stake in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 207 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.